China's drug regulator approved the metformin empagliflozin tablets produced by Chongqing Taiji Industry (SHA:600129) subsidiary Southwest Pharmaceutical, according to a Thursday filing with the Shanghai bourse.
The drug is used to control blood sugar in type 2 diabetes patients.